A certain biopharmaceutical company encountered a time conflict between patent application and academic paper publication in the development of new anti-tumor targeted drugs. The "small molecule inhibitor based on dual target synergistic effect" developed by the company achieved a 72% inhibition rate on specific tumors in animal experiments. The R&D team is eager to increase industry influence by publishing papers in top journals. However, if key data such as the structure and mechanism of action of the core compound are made public in advance, it will lead to the loss of novelty in subsequent patent applications, directly affecting the investment of hundreds of millions of yuan in new drug research and development.

After our team deeply intervened, we first conducted a graded evaluation of the technological achievements, clarifying the boundary between "core protected elements" and "publicly available academic content". By jointly sorting out experimental data with the R&D team, 8 items including compound molecular structure, key active groups, and synthesis process need to be included in patent protection, while 5 items such as animal experimental model construction and safety evaluation methods can be used as paper materials. In response to the time conflict between patents and papers, a "patent priority+strategic disclosure" plan is formulated: first submit a patent application containing core technology, use the "temporary protection" function of the patent application document, publish the paper after the patent is published, and use a general formula to express the core structure in the paper, hiding specific activity data.

During the patent writing stage, assisted the company in completing three invention patent applications, among which "a dual target anti-tumor compound and its preparation method" adopts a broad claim layout, covering compound formulas, derivatives, and pharmaceutical uses, while supplementing a large amount of experimental data in the specification to enhance patent stability. During the publication stage of the paper, the guidance team adjusted the wording and used the publicly available content of the patent as the basis, focusing on the new findings of the mechanism of action research. The final paper was successfully published in the journal Cancer Research with an impact factor of 8.5.

After the implementation of the plan, the patent application was successfully authorized, and the protection scope fully covered the core technology. The enterprise completed a Series A financing of 120 million yuan based on this patent. After the publication of academic papers, the company gained high attention from the industry and established cooperation with three clinical institutions, accelerating the process of drugs entering the clinical trial stage. Through the collaborative layout of patents and papers, enterprises not only protect their core technologies, but also achieve effective transformation of academic achievements, laying a dual foundation for the subsequent launch of new drugs.